Free Newsletter
Vaccine shortage yields political peril
While it's clear that manufacturing practice missteps can have financial consequences, it turns out that manufacturing capacity issues can have political consequences. Canada's National Post reports that GlaxoSmithKline's production delays for H1N1 vaccine are causing more than just PR headaches for the government.
Health Minister Leona Aglukkaq is under fire after the decision last week to suspend H1N1 vaccination in Alberta clinics because of the vaccine shortage. Alberta's opposition Liberals are calling for the health minister to resign over the matter. Canadian officials learned that insufficient supplies of only 625,000 doses were available for shipment to clinics.
"I'm disappointed," Aglukkaq says in a press report. "GSK overstated what they would be able to produce." The capacity shortfall is being blamed on the drug giant's need to produce an un-adjuvanted vaccine for pregnant women.
- read the article
Related Articles:
Drugmakers tagged with vaccine delays
Swine flu cases explode as vax shortfall worsens
Swine flu offers a new lift to booming vax business
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
